Sumitomo Mitsui DS Asset Management Company Ltd Increases Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 0.6% during the fourth quarter, HoldingsChannel reports. The fund owned 32,552 shares of the medical device company’s stock after purchasing an additional 198 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Cooper Companies were worth $2,993,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Ashton Thomas Securities LLC purchased a new stake in Cooper Companies in the third quarter valued at $25,000. Covestor Ltd increased its holdings in shares of Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 200 shares during the period. Brown Brothers Harriman & Co. raised its position in Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 275 shares during the last quarter. Friedenthal Financial acquired a new stake in Cooper Companies during the 3rd quarter worth $50,000. Finally, Cromwell Holdings LLC purchased a new position in Cooper Companies during the 3rd quarter worth $52,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Wells Fargo & Company upped their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, December 6th. Citigroup reduced their price objective on Cooper Companies from $116.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, December 6th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Morgan Stanley lowered their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Friday, December 6th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $117.00.

Cooper Companies Price Performance

Cooper Companies stock opened at $93.57 on Monday. The company has a market cap of $18.67 billion, a P/E ratio of 47.98, a price-to-earnings-growth ratio of 2.41 and a beta of 1.00. The Cooper Companies, Inc. has a one year low of $84.76 and a one year high of $112.38. The business has a fifty day moving average of $94.99 and a two-hundred day moving average of $99.85. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.00 by $0.04. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter last year, the business earned $0.87 earnings per share. The business’s revenue for the quarter was up 9.8% compared to the same quarter last year. As a group, analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.